Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid, used in prostate cancer

Indications

Cabazitaxel is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

Dosage

IV; Dosage is based on calculation of the Body Surface Area (BSA), and is 20 mg/m2 administered as a one-hour intravenous infusion every three weeks in combination with oral prednisone 10 mg administered daily throughout JEVTANA treatment. Dose modification is required in toxicity or liver impairment .

Contra-Indications

neutrophil counts of d” 1,500/mm³, history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate , severe hepatic impairment (total bilirubin >3 × ULN)

Special Precautions

Use with caution in hepatic impairment Paediatric: The safety and effectiveness in pediatric patients have not been established. Pregnancy: N.A. Lactation: N.A. Elderly: Elderly patients (>65 years of age) may be more likely to experience certain adverse reactions. Use with caution.

Side Effects

anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, alopecia, neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia, Increased Toxicities in Elderly Patients, Hypersensitivity Reactions, Gastrointestinal Adverse Reactions, Renal Failure, Urinary Disorders Including Cystitis, Respiratory Disorders.

Drug Interactions

Avoid coadministration with strong CYP3A inhibitors.